Department of Critical Care Medicine, Zhongnan Hospital of Wuhan University, Wuhan, China.
Department of Cardiology, David Geffen School of Medicine, University of California, Los Angeles, CA, USA.
Ren Fail. 2022 Dec;44(1):1280-1288. doi: 10.1080/0886022X.2022.2107544.
The coronavirus disease-2019 (COVID-19) outbreak has been declared a global pandemic. COVID-19-associated acute kidney injury (COVID-19 AKI) is related to a high mortality rate and serves as an independent risk factor for hospital death in patients with COVID-19. Early diagnosis would allow for earlier intervention and potentially improve patient outcomes. The goal of early identification of AKI has been the primary impetus for AKI biomarker research, and several kidney injury biomarkers have been demonstrated to be beneficial in predicting COVID-19 AKI as well as disease progression in COVID-19. Furthermore, such data provide valuable insights into the molecular mechanisms underlying this complex and unique disease and serve as a molecular phenotyping tool that could be utilized to direct clinical intervention. This review focuses on a number of kidney injury biomarkers, such as CysC, NAGAL, KIM-1, L-FABP, IL-18, suPAR, and [TIMP-2] • [IGFBP7], which have been widely studied in common clinical settings, such as sepsis, cardiac surgery, and contrast-induced AKI. We explore the role of kidney injury biomarkers in COVID-19 and discuss what remains to be learned.
新型冠状病毒病 2019（COVID-19）疫情已被宣布为全球大流行。COVID-19 相关的急性肾损伤（COVID-19 AKI）与高死亡率相关，是 COVID-19 患者住院死亡的独立危险因素。早期诊断可实现更早干预，并可能改善患者预后。AKI 的早期识别目标一直是 AKI 生物标志物研究的主要动力，已经有几种肾脏损伤生物标志物被证明有助于预测 COVID-19 AKI 以及 COVID-19 疾病进展。此外，此类数据为深入了解这种复杂而独特的疾病的分子机制提供了有价值的见解，并可作为一种分子表型工具，用于指导临床干预。本综述重点介绍了一些肾脏损伤生物标志物，如 CysC、NAGAL、KIM-1、L-FABP、IL-18、suPAR 和 [TIMP-2]•[IGFBP7]，它们在脓毒症、心脏手术和造影剂诱导的 AKI 等常见临床情况下已得到广泛研究。我们探讨了肾脏损伤生物标志物在 COVID-19 中的作用，并讨论了仍需了解的问题。
